| XLS |
|
|
|
|
|
| ||
|
€ million |
Q3 2012 |
Q3 2011* |
Jan.–Sept. |
Jan.–Sept. | ||
| ||||||
|
Sales |
2,721.7 |
2,434.3 |
8,028.7 |
7,381.4 | ||
|
Royalty, license and commission income |
119.4 |
97.3 |
309.4 |
269.3 | ||
|
Total revenues |
2,841.0 |
2,531.6 |
8,338.1 |
7,650.7 | ||
|
|
|
|
|
| ||
|
Cost of sales |
–787.6 |
–679.1 |
–2,344.1 |
–2,077.9 | ||
|
Gross profit |
2,053.4 |
1,852.5 |
5,994.0 |
5,572.8 | ||
|
|
|
|
|
| ||
|
Marketing and selling expenses |
–598.0 |
–584.6 |
–1,801.8 |
–1,778.5 | ||
|
Royalty, license and commission expenses |
–161.6 |
–133.9 |
–433.4 |
–363.7 | ||
|
Administration expenses |
–141.6 |
–132.6 |
–420.6 |
–397.1 | ||
|
Other operating expenses and income |
–245.1 |
–86.3 |
–878.4 |
–301.5 | ||
|
Research and development |
–370.8 |
–370.2 |
–1,156.5 |
–1,117.3 | ||
|
Amortization of intangible assets |
–218.2 |
–212.9 |
–651.8 |
–780.1 | ||
|
Investment result |
– |
–0.1 |
0.5 |
1.9 | ||
|
Operating result (EBIT) |
318.1 |
331.8 |
651.9 |
836.4 | ||
|
|
|
|
|
| ||
|
Financial result |
–58.2 |
–72.4 |
–193.9 |
–219.0 | ||
|
Profit before income tax |
260.0 |
259.4 |
458.0 |
617.5 | ||
|
|
|
|
|
| ||
|
Income tax |
–71.3 |
–32.3 |
–154.7 |
–135.6 | ||
|
Profit after tax |
188.7 |
227.2 |
303.3 |
481.9 | ||
|
|
|
|
|
| ||
|
of which attributable to Merck KGaA shareholders (net income) |
185.5 |
223.9 |
294.9 |
473.6 | ||
|
of which non-controlling interest |
3.2 |
3.3 |
8.3 |
8.2 | ||
|
|
|
|
|
| ||
|
Earnings per share (in €) |
|
|
|
| ||
|
basic |
0.85 |
1.03 |
1.36 |
2.18 | ||
|
diluted |
0.85 |
1.03 |
1.36 |
2.18 | ||